AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31661579
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (C-group)
Trial: 29622380
Drug: Tralokinumab 600
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab 600 mg
Trial: 29622380
Drug: Tralokinumab (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab (150, 300, or 600 mg)
Trial: 29622380
Drug: Tralokinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab (300 mg)
Trial: 28258661
Drug: G-CEM LinkAceTM
RxNorm normalized name: CEM-Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CEM LinkAceTM
Trial: 25328082
Drug: G. kola
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. kola 12.5 g once daily for 7 days (group A)
Trial: 25328082
Drug: G. kola
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. kola 12.5 g twice daily for 6 days and once on the seventh day (group B)
Trial: 25328082
Drug: Quinine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine with G. kola
Trial: 1587589
Drug: EcSf2a-1 vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-1 vaccine (1.0 x 10(9) CFU)
Trial: 1587589
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine (1.5 x 10(11) CFU in three doses)
Trial: 1587589
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine (2.5 x 10(9) CFU)
Trial: 1587589
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine (1.8 x 10(10) CFU)
Trial: 1587589
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine (1.2 to 2.5 x 10(9) CFU in three doses)
Trial: 24849793
Drug: Wii Sports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wii Sports Resort training plus usual therapy
Trial: 15758622
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 3 mg enema once daily for 6 weeks
Trial: 15758622
Drug: 5-ASA (mesalamine)
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ASA (mesalamine) 1 g enema daily for 6 weeks
Trial: 10323605
Drug: HGH (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGH (0.1 mg/kg/day)
Trial: 12637255
Drug: Oxandrolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (20 mg/day)
Trial: 8759894
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) (8 mg/m2, i.v., days 1-5)
Trial: 8759894
Drug: Zorubicin (ZRB)
RxNorm normalized name: zorubicin
DrugBank: Zorubicin (DB11618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zorubicin (ZRB) (200 mg/m2, i.v., days 1-4)
Trial: 8759894
Drug: Consolidation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation therapy with high-dose Ara-C (3 g/m2, 3 h infusion, q 12 h, days 1-4) and m-Amsa (100 mg/m2/d, i.v., days 5-7)
Trial: 6352185
Drug: Indapamide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.0 mg/day for 4 weeks
Trial: 6352185
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg/day for 4 weeks
Trial: 6352185
Drug: Indapamide 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 5.0 mg/day for 4 weeks
Trial: 6352185
Drug: Indapamide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (all doses)
Trial: 26909960
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii pills (orally administered) for three courses of treatment, each consisting of 4 weeks, in addition to conventional western medicine.
Trial: 26909960
Drug: Observation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation group (T. wilfordii + conventional medicine).
Trial: 26909960
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional medicine).
Trial: 22382219
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9%) hydration at 1 mL/kg/h for 12 hours before and 24 hours after PCI
Trial: 20801446
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 supplementation
Trial: 17096666
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg/ml intravenously every 6 h during the first post-operative day (total, 400 mg/24 h)
Trial: 2104438
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of sodium heparin
Trial: 2104438
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of sodium heparin
Trial: 697222
Drug: Smoking marihuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking marihuana cigarettes containing 6 mg of delta‐9‐tetrahydrocannabinol
Trial: 30802822
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine 80 mg/m2 (first cycle at 60 mg/m2, escalated to 80 mg/m2 in the absence of grade 3/4 toxicity)
Trial: 30802822
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel 80 mg/m2 on days 1, 8, and 15 every 3 weeks
Trial: 30802822
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel
Trial: 24076689
Drug: External valvuloplasty
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External valvuloplasty for small subcutaneous veins
Trial: 21880848
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D (1 g Ca/400 IU vitamin D daily)
Trial: 16446329
Drug: 90Y‐muHMFG1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90Y‐muHMFG1 plus standard treatment
Trial: 11866284
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose HBV vaccination (40 microg administered monthly for 3 months)
Trial: 11866284
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose HBV vaccination (booster dose of 80 microg for nonresponders)
Trial: 9642936
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of inactivated influenza vaccine
Trial: 9642936
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of inactivated influenza vaccine
Trial: 335348
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b vaccine
Trial: 335348
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group A meningococcal vaccine)
Trial: 26456573
Drug: Paclitaxel 90
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with everolimus 10 mg daily (Arm 1)
Trial: 26456573
Drug: Paclitaxel 90
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with placebo (Arm 2)
Trial: 23245582
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg IV iron sucrose
Trial: 23245582
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg IV iron sucrose
Trial: 23245582
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg IV iron sucrose
Trial: 19393845
Drug: ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoprofen 100 mg + acetaminophen 1000 mg
Trial: 19393845
Drug: ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoprofen 100 mg
Trial: 15669418
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone (IV bolus of 2mg/kg in 15 minutes, followed by maintenance infusion of 0.0067 mg/kg/min until conversion to sinus rhythm or for up to 90 minutes)
Trial: 15669418
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching saline solution administered in the same fashion)
Trial: 11211369
Drug: Imipramine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine combined with cognitive-behavioral therapy
Trial: 11211369
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with cognitive-behavioral therapy
Trial: 11211369
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (including psychotropic medication and outpatient therapy)
Trial: 9368196
Drug: Citalopram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram infusion (20 mg i.v. at 14:20-14:50 h) after a night of undisturbed sleep
Trial: 9368196
Drug: Citalopram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram infusion (20 mg i.v. after a night of sleep deprivation
Trial: 27537603
Drug: Kestose, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kestose, administered orally every day for 12 weeks
Trial: 24330422
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (100,000 IU for infants <12 months & 200,000 IU for children >12 months) and 10 mg daily zinc for 6 months
Trial: 17383342
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) for 3 weeks before surgery
Trial: 15102997
Drug: Uracil-tegafur (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uracil-tegafur (250 mg of tegafur per square meter of body-surface area per day) for two years
Trial: 11476795
Drug: 17alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17alpha-hydroxyprogesterone caproate (17-HPC) 341 mg every 3 days
Trial: 11476795
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (P) 50 mg daily
Trial: 7975797
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fragmin) - 2500‐5000 anti‐Xa‐units once daily for 10 days
Trial: 7975797
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (Liquemin) - 5000 IU two to three times daily for 10 days
Trial: 7975797
Drug: Heparin induced
RxNorm normalized name: HIT (Heparin induced thrombocytopenia) antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin induced thrombocytopenia
Trial: 2692199
Drug: Intravenous prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostaglandin E1 (PGE1) - 60 micrograms, 3 ampoules, infused daily over 3 hours for 6 weeks
Trial: 2692199
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 3 ampoules of alpha-CD, infused daily over 3 hours for 6 weeks
Trial: 30054906
Drug: Adequate hydration
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate hydration with nitrates (isosorbide dinitrate combined with isotonic saline at 1.5 mL/kg/h during perioperative period)
Trial: 25952653
Drug: Telemonitoring intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemonitoring intervention (home BP telemonitors, medication adjustments by pharmacists, lifestyle advice via telephone visits)
Trial: 19595382
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (2.4 g/d)
Trial: 11566079
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (15 mg) plus fentanyl (25 microgram)
Trial: 11566079
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (15 mg) alone
Trial: 2979276
Drug: Liquid antacid
RxNorm normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid antacid (neutralizing capacity 120 mmol per day)
Trial: 2979276
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cimetidine
Trial: 2979276
Drug: Placebo pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pain tablets
Trial: 2979276
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of therapy (general)
Trial: 31430366
Drug: Antibiotic Review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic Review Kit (ARK) intervention
Trial: 9513749
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) infusion of TRP 100 mg/kg
Trial: 3050616
Drug: Defibrotide (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (800 mg/i.v.)
Trial: 3050616
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (15,000 UI/s.c.)
Trial: 3050616
Drug: Defibrotide (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (800 mg/i.v.) and Calcium heparin (15,000 UI/s.c.)
Trial: 27915408
Drug: Copanlisib 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib 0.4 mg/kg
Trial: 27915408
Drug: Copanlisib 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib 0.8 mg/kg
Trial: 27915408
Drug: Copanlisib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib (both doses)
Trial: 31257614
Drug: Risankizumab 18
RxNorm normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 18 mg SC
Trial: 31257614
Drug: Risankizumab 90
RxNorm normalized name: Risankizumab 90.361 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 90 mg SC
Trial: 31257614
Drug: Risankizumab 300
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab 300 mg SC
Trial: 31257614
Drug: Risankizumab 200
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab 200 mg IV
Trial: 31257614
Drug: Risankizumab 600
RxNorm normalized name: RISANKIZUMAB 600 mg in 10 mL INTRAVENOUS INJECTION [Skyrizi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 600 mg IV
Trial: 31257614
Drug: Risankizumab 1200
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab 1200 mg IV
Trial: 31257614
Drug: Risankizumab 75
RxNorm normalized name: risankizumab 75 mg/0.83 mL subcutaneous kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 75 mg SC
Trial: 31257614
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg SC
Trial: 29912798
Drug: encenicline 1
RxNorm normalized name: Encenicline
DrugBank: Encenicline (DB11726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encenicline 1 mg twice daily
Trial: 29912798
Drug: encenicline 1
RxNorm normalized name: Encenicline
DrugBank: Encenicline (DB11726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encenicline 1 mg twice daily + NRT patch
Trial: 29912798
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + NRT patch
Trial: 29912798
Drug: encenicline plus
RxNorm normalized name: Encenicline
DrugBank: Encenicline (DB11726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encenicline plus placebo patch
Trial: 17667331
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available individual dosage forms (reference treatment)
Trial: 15780109
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamin supplementation (1 mg of folic acid, 10 mg pyridoxal 5'-phosphate, and 6 µg of vitamin B12)
Trial: 20378616
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (buserelin)
Trial: 7797602
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg/day, oral)
Trial: 759664
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer treatment
Trial: 28763451
Drug: Stepped-care program
RxNorm normalized name: PEPPLUS SPECIAL SKIN CARE LIFTING PROGRAM KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care program delivered by trained practice nurses over one year, consisting of watchful waiting, guided self-help, problem solving treatment, and referral to the general practitioner.
Trial: 26469750
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (30 mg DHA/kg/d)
Trial: 22035986
Drug: TARGET (trauma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARGET (trauma affect regulation: guide for education and therapy)
Trial: 22035986
Drug: PCT (present
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT (present centered therapy)
Trial: 18957532
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg simvastatin daily for 8 weeks
Trial: 15531767
Drug: Trandolapril at
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril at a target dose of 4 mg per day
Trial: 11309014
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 and 0.9 mg/kg
Trial: 9444014
Drug: Mebendazole 25
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole 25 mg single dose
Trial: 9444014
Drug: Mebendazole 50
RxNorm normalized name: mebendazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 50 mg single dose
Trial: 9444014
Drug: Mebendazole 75
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole 75 mg single dose
Trial: 9444014
Drug: Mebendazole 100
RxNorm normalized name: mebendazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 100 mg twice daily for 3 days
Trial: 27002108
Drug: tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 10 mg twice daily + MTX
Trial: 27002108
Drug: tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 10 mg twice daily (monotherapy)
Trial: 27002108
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + placebo (MTX monotherapy)
Trial: 24645942
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment in the intensive care unit (control group)
Trial: 15829527
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (2000 IU daily)
Trial: 7554523
Drug: Nitrendipine 2
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 2 x 5 mg daily (normotensive group)
Trial: 7554523
Drug: Nitrendipine 2
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 2 x 10 mg - 2 x 20 mg daily (hypertensive group)
Trial: 7356905
Drug: Indoprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (200 mg)
Trial: 7356905
Drug: Ibuprofen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (300 mg)
Trial: 30935539
Drug: Nano-curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin supplementation (80 mg for 8 weeks)
Trial: 20816118
Drug: Fenofibrate/pravastatin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate/pravastatin combination therapy